

Press Release

DSM (China) Ltd.
DSM China Corporate Communications

476 Libing Road, Zhangjiang Hi-Tech Park
201203 Pudong New Area, Shanghai,
China

August 8, 2013 Shanghai, China

DSM delivers higher profits; full year outlook unchanged

- DSM records 19% higher Q2 EBITDA versus Q2 2012 (€345 million versus €290 million)
- Nutrition EBITDA up 28% versus Q2 2012 driven by acquisitions and organic growth
- Materials Sciences continues to deliver a solid performance
- Q2 cash flow from operating activities €231 million, higher than Q2 2012 and Q1 2013
- Core earnings per share Q2 2013 up 28% compared to Q2 2012
- Interim dividend of €0.50, in line with DSM's dividend policy
- Outlook 2013 unchanged, moving towards EBITDA of €1.4 billion
- Sales to China amounted to USD 403 million, versus USD 430 million in Q2 2012 as healthy growth in most businesses could not compensate for lower sales prices for caprolactam in China

Royal DSM, the Life Sciences and Materials Sciences company, reported a second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013. The improvement compared to Q2 2012 was realized despite a negative caprolactam effect of €20 million and a challenging macro-economic environment, which mainly affected Materials Sciences.

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said:

"We are pleased to report that the momentum in our Nutrition business that we saw at the end of Q1 continued into Q2. Nutrition, with its higher profits and healthy margins, is demonstrating the quality of its broad offering across the value chain. Materials Sciences' profit remained at the same level as last year despite a negative caprolactam impact of €20 million and a challenging market environment."

"For the rest of this year, we will continue to fully focus on operational performance and on the integration of our acquisitions, ensuring the capture of synergies. In addition, the early successes of our profit improvement initiatives leave us confident that this group-wide program is well on track. We expect strong EBITDA growth in 2013, moving towards €1.4 billion."

"Despite the continued challenging macro-economic environment, DSM in China achieved healthy growth in most of its businesses in the second quarter of this year," said DSM China President Dr. Jiang Weiming. *"Our business portfolio both in Life Sciences and Materials Sciences areas covers well what is demanded in the market. We have full confidence for the long term future of China and the industry."*

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity,

environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 23,500 employees deliver annual net sales of around €9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

DSM began trading with China in 1963 and established its first China sales office and first manufacturing facility in early 1990s. The company currently has 40 affiliates in China including 26 manufacturing sites and employs about 3,500 people. DSM China regional headquarters and China Science and Technology Center is located in Shanghai. DSM's business is growing healthily and steadily in China with revenue of USD1.7 billion in 2012.

Media enquiries:

Wendy Zhang
DSM China Limited

Tel: 021 - 6141 8003
Email: wendy.zhang@dsm.com